Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Sciarra
Alessandro
A
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D015995:Prevalence; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000453:epidemiology; D011687:Purines / Q000627:therapeutic use; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D014555:Urination Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D011799:Quinazolines; D013450:Sulfones; C047638:alfuzosin; D000068677:Sildenafil Citrate